Cristina Álvarez-Escolá1, Eva María Venegas-Moreno2, Juan Antonio García-Arnés3, Concepción Blanco-Carrera4, Mónica Marazuela-Azpiroz5, María Ángeles Gálvez-Moreno6, Edelmiro Menéndez-Torre7, Javier Aller-Pardo8, Isabel Salinas-Vert9, Eugenia Resmini10, Elena María Torres-Vela11, María Ángeles Gonzalo-Redondo12, Ricardo Vílchez-Joya13, María Paz de Miguel-Novoa14, Irene Halperín-Rabinovich15, Concepción Páramo-Fernández16, Guillermo de la Cruz-Sugranyes17, Aude Houchard18, Antonio Miguel Picó-Alfonso19. 1. Endocrinology and Nutrition Department, Hospital Universitario La Paz, Madrid, Spain. Electronic address: escola.cristina@gmail.com. 2. Endocrinology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain. 3. Endocrinology and Nutrition Service, Hospital Regional Universitario de Málaga, Málaga, Spain. 4. Endocrinology Department, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain. 5. Endocrinology Department, Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Instituto Princesa, Madrid, Spain. 6. Endocrinology Service, Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain. 7. Endocrinology and Nutrition Department, Hospital Universitario Central de Asturias, Oviedo, Spain. 8. Endocrinology Department, Neuroendocrinology & Endocrine Oncology Unit, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. 9. Endocrinology and Nutrition Department, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain. 10. Hospital Sant Pau, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), IIB-Sant Pau, Barcelona, Spain; Universitat Autònoma de Barcelona, Barcelona, Spain. 11. Endocrinology and Nutrition, Complejo Hospitalario Universitario, Granada, Spain. 12. Endocrinology and Nutrition Department, Fundación Jiménez Díaz, Madrid, Spain. 13. Endocrinology and Nutrition Service, Hospital Universitario Virgen de las Nieves, Granada, Spain. 14. Endocrinology Department, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Madrid, Spain. 15. Endocrinology Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain. 16. Endocrinology and Nutrition Department, Complejo Hospitalario Xeral-Cies de Vigo, Vigo, Pontevedra, Spain. 17. Medical Department, IPSEN PHARMA S.A., L'Hospitalet de Llobregat, Barcelona, Spain. 18. Statistics Department, IPSEN PHARMA, Boulogne-Billancourt, France. 19. Endocrinology Department, Hospital General Universitario de Alicante-ISABIAL-FISABIO, Alicante, Spain.
Abstract
OBJECTIVES: The ACROSTART study was intended to determine the time to achieve normalization of GH and IGF-I levels in responding patients with acromegaly administered different dosage regimens of lanreotide Autogel (Somatuline® Autogel®). METHODS: From March 2013 to October 2013, clinical data from 57 patients from 17 Spanish hospitals with active acromegaly treated with lanreotide for ≥4 months who achieved hormonal control (GH levels <2.5ng/ml and/or normalized IGF-I levels in ≥2 measurements) were analyzed. The primary objective was to determine the time from start of lanreotide treatment to hormonal normalization. RESULTS: Median patient age was 64 years, 21 patients were male, 39 patients had undergone surgery, and 14 patients had received radiotherapy. Median hormonal values at start of lanreotide treatment were: GH, 2.6ng/ml; IGF-I, 1.6×ULN. The most common starting dose of lanreotide was 120mg (29 patients). The main initial regimens were 60mg/4 weeks (n=13), 90mg/4 weeks (n=6), 120mg/4 weeks (n=13), 120mg/6 weeks (n=6), and 120mg/8 weeks (n=9). An initial treatment regimen with a long interval (≥6 weeks) was administered in 25 patients. Mean duration of lanreotide treatment was 68 months (7-205). Median time to achieve hormonal control was 4.9 months. Injections were managed without healthcare assistance in 13 patients. Median number of visits to endocrinologists until hormonal control was achieved was 3. Fifty-one patients were "satisfied"/"very satisfied" with treatment and 49 patients did not miss any dose. CONCLUSIONS: Real-life treatment with lanreotide Autogel resulted in early hormonal control in responding patients, with high treatment adherence and satisfaction despite disparity in starting doses and dosing intervals.
OBJECTIVES: The ACROSTART study was intended to determine the time to achieve normalization of GH and IGF-I levels in responding patients with acromegaly administered different dosage regimens of lanreotide Autogel (Somatuline® Autogel®). METHODS: From March 2013 to October 2013, clinical data from 57 patients from 17 Spanish hospitals with active acromegaly treated with lanreotide for ≥4 months who achieved hormonal control (GH levels <2.5ng/ml and/or normalized IGF-I levels in ≥2 measurements) were analyzed. The primary objective was to determine the time from start of lanreotide treatment to hormonal normalization. RESULTS: Median patient age was 64 years, 21 patients were male, 39 patients had undergone surgery, and 14 patients had received radiotherapy. Median hormonal values at start of lanreotide treatment were: GH, 2.6ng/ml; IGF-I, 1.6×ULN. The most common starting dose of lanreotide was 120mg (29 patients). The main initial regimens were 60mg/4 weeks (n=13), 90mg/4 weeks (n=6), 120mg/4 weeks (n=13), 120mg/6 weeks (n=6), and 120mg/8 weeks (n=9). An initial treatment regimen with a long interval (≥6 weeks) was administered in 25 patients. Mean duration of lanreotide treatment was 68 months (7-205). Median time to achieve hormonal control was 4.9 months. Injections were managed without healthcare assistance in 13 patients. Median number of visits to endocrinologists until hormonal control was achieved was 3. Fifty-one patients were "satisfied"/"very satisfied" with treatment and 49 patients did not miss any dose. CONCLUSIONS: Real-life treatment with lanreotide Autogel resulted in early hormonal control in responding patients, with high treatment adherence and satisfaction despite disparity in starting doses and dosing intervals.